Ofer Toledano

Company: Sol Gel Technologies

Job title: VP R&D

Seminars:

Panel Discussion: Can Topical and Systemic Therapies Each Find Their Place in the Future of Dermatology Drug Development? 4:30 pm

How should we balance the clinical and commercial drivers behind topical and systemic innovation, especially as realworld prescribing habits continue to favor topicals? How are these approaches viewed from the patient, regulator and investor perspective? Which factors, including disease severity, body surface area, and treatment setting, best guide whether a topical, systemic, or combination approach…Read more

day: Day One PM

Advancing Topical Therapies for Rare Dermatologic Diseases for Safer, More Targeted Treatment 2:30 pm

Enabling topical delivery of novel molecules, aiming to reduce systemic exposure and adverse events in rare skin conditions Understanding the different regulatory and funding approaches required for the rare space SGT-610, currently in Phase 3 for Gorlin Syndrome, offers an alternative to systemic hedgehog inhibitors with a potentially improved safety profile SGT-210, in Phase 1…Read more

day: Day Two PM